Procter & Gamble's stock price soared 79 percent when A.G. Lafley was CEO before, reports CNBC's Jackie DeAngelis. Bob Damon, Korn/Ferry International, and Fred Hassan, Warburg Pincus, discuss what bringing Lafley back says about the overall executive talent pool.» Read More
Amid the gloomy comments from auto executives at the Geneva Motor Show, the unveilings of several important new models are being overshadowed. Take the new Ford Fiesta. This compact car is being sold in Europe, but the design cues and architecture behind this car will be the underpinnings of compact cars the automaker will roll out in the U.S. in the future.
Expensive oil and a coal shortage will only push this stock higher, Cramer says.
On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...
Fortress Investment Group came to market at private equity's peak. Too bad no one but the company knew the party was over.
It's Cramer's favorite of his Fab Five agriculture stocks. Don't miss this interview with the CEO.
Only 39 percent of big investors think the way U.S. companies reward top executives has helped improve corporate performance, and most believe that top managers have too much influence in setting their own pay, a new study has found.
German drugs and chemicals group Bayer missed fourth-quarter earnings expectations Thursday, sending shares 4.7 percent lower on the DAX, but CEO Werner Wenning told CNBC he remains optimistic about the company’s outlook for this year.
When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.
Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.
This company's turned a "trifecta of negativity" into pure positivity.
A tough fourth quarter sunk the stock. But Ray Milchovich doesn't want people giving up yet.
With the stock price recently cut in half, Cramer has some concerns. Find out how the chief executive responded.
Austrian oil and gas group OMV reported on Tuesday a forecast-beating 23 percent increase in clean operating earnings in the fourth quarter on favourable crude prices and improved refining margins.
CEO Bob Simpson trumpets the benefits of natural gas, and explains how he'll avoid butting heads with Hugo Chavez.
According to The Center for Responsive Politics' web site Pfizer Chairman and CEO Jeff Kindler has opened his wallet again for Sen. Hillary Clinton. You can see his latest "give" here. Twice now within the past year Kindler has given the maximum amount ($2,300) an individual can contribute to a candidate.
CNBC's Squawk Box was in Miami this morning, and the Squawk crew interviewed Miami-based CEOs on everything from real estate to healthcare.
I hear it all the time from car buffs, Chrysler fans, and those who lament the struggles of the American automakers. It goes something like this: "Why is Chrysler cutting back here in the U.S. and looking to expand overseas?"
Bond insurer MBIA said Tuesday that former Chairman and CEO Joseph "Jay" Brown was returning to replace current CEO Gary Dunton as the company, beset by mortgage-related losses, scrambles to maintain a top credit rating.
Liechtenstein's Crown Prince Alois on Tuesday accused Germany of launching an attack on the principality's sovereignty by paying an informer for bank details in a massive tax fraud investigation.
Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.